We listen,
learn, and
deliver.
We are on a mission to deliver medicines that address what matters most.
Tisento is Italian
for “I hear you.”
At Tisento, we believe meaningful innovation starts with listening.
We listen to clinicians, patients, and families to better understand unmet medical needs and the challenges of care. We bring those insights together with scientific evidence to guide our research and the clinical trials we design.
Significant unmet needs. Meaningful opportunities.
We are advancing undisclosed programs addressing significant unmet needs in serious and rare neurological disorders.
We focus on areas where compelling science and clear patient need create opportunities to meaningfully change care.
Small team. Deep experience. Big goals.
We are a lean, agile team of industry veterans committed to developing innovative medicines that improve people’s lives. Our shared dedication to patients, collective experience, and use of advanced technologies and data-driven approaches enable us to move quickly, work efficiently, and focus on developing medicines that can make a meaningful difference for patients.
Allison Burton
Regulatory Affairs Associate
Jennifer Chickering, PhD
Vice President, Program Leadership
Sara Ciarametaro, MBA
Senior Director, Finance and Operations
Chad Glasser, PharmD, MPH
Vice President, Clinical Research
Peter Hecht, PhD
Chief Executive Officer
Bill Kissel, PhD
Vice President, Pharmaceutical Operations
Kristin Lurk, MS, PMP
Executive Director, Program Management
Todd Milne, PhD
Chief Operating Officer
Marian Rafferty
Chief of Staff
Wheatley Spence, MS
Head of Regulatory Affairs
Marta Cavero Tomas, PhD
Vice President, IP, Contracts, and Licensing
Matt Webster, MS
Vice President, Clinical Operations
Our board of directors
Paulina Hill
Sanofi Ventures, Board Member
Bryan Roberts
Venrock, Board Member
Peter Hecht, PhD
Tisento, Board Member
Strong partnerships. Expanded impact.
We work closely with an extensive, global network of trusted advisors, thought leaders, advocacy groups, technology and innovation leaders, and other collaborators who are partners in our mission. Their diverse expertise and perspectives complement our experienced team, extending our capabilities and enabling us to move quickly and accomplish more together on behalf of patients.
In addition, we are proud of our top-tier investor partners who share our vision and power our innovation.
Our investor syndicate also includes other top public and private investors, including our CEO, Peter Hecht.
Contact us
We are headquartered in Cambridge, MA, with our primary office in Boston.
Tisento Therapeutics
98 North Washington Street, Suite 580
Boston, MA 02114
We would love to hear from you! Reach out through the channels below.
General inquiries:
hello@tisentotx.com
Partnering/collaboration inquiries:
partnering@tisentotx.com
Connect with us on social media:
